At the American Society of Hematology (ASH) meeting in December 2025, US cardiologist Dr Orly Leiva, who has a special interest in myeloproliferative neoplasms, presented posters about MPNs and cardiovascular issues. Dr Leiva notes that this is a very under-researched field.
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms
The abstract to the poster explains:
- ‘Statin use in the general population for primary and secondary prevention has been shown to reduce adverse cardiovascular (CV) events.’
- ‘Additionally, prior epidemiologic studies have showed an association between statin use and decreased risk of incident MPNs.’
- ‘However, the role of statins in preventing major adverse CV events and hematologic progression has not been systematically assessed in MPNs and remains unclear.’
The abstract outlines the conclusions:
- ‘In patients with MPNs, statin use was associated with a reduced risk of arterial thrombosis and heart failure hospitalization, but not with hematologic progression or all-cause mortality.’
- ‘Notably, the intensity of statin therapy did not correlate with clinical outcomes among statin-treated patients.’
- ‘These findings suggest that statins may provide meaningful cardiovascular protection in individuals with MPN, yet appear to be underutilized even among those with established clinical indications.’
- ‘Further prospective studies are warranted to better define the role of statins and optimize cardiovascular risk management in this population.’
The full abstract for ASH is freely available to read HERE.
A research article has subsequently been published in Blood Advances and the full article is free to download as a PDF HERE
